Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IASO BIO to Start Trials of CAR-T in Leukemia Patients

publication date: Jun 3, 2021

Nanjing IASO Bio has been approved to start China clinical trials of CT120, its second CAR-T candidate to enter clinical trials. The company will test its fully human CD19/CD22 dual-targeting chimeric antigen receptor-T cell therapy in patients with relapsed/refractory B-acute lymphoblastic leukemia. Two years ago, IASO and its partner, Suzhou Innovent, started a Phase Ib/II trial of their jointly developed lentiviral vector/CAR-T candidate, which is designed to treat multiple myeloma patients who have progressed after an earlier CAR-T treatment. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital